Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma

Br J Haematol. 2012 Jul;158(2):290-292. doi: 10.1111/j.1365-2141.2012.09137.x. Epub 2012 Apr 26.

¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Weill-Cornell Medical College, New York, NY, USA.
³ Department of Medicine, UCLA Medical Center, Los Angeles, CA, USA.
⁴ Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
⁵ Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
⁶ Millennium Pharmaceuticals, The Takeda Oncology Company, Cambridge, MA, USA.
⁷ NYU Langone Medical Center, NYU Cancer Institute, New York, NY, USA.

No abstract available

Publication types